We believe that Cell C’s underperformance, significant debt servicing obligations and foreign debt exposure continue to weigh down BLU’s valuation. With the disclosure of more accurate financial information on Cell C we have attempted to model the associate more accurately. By our estimates, even with the additional debt raised by Cell C, the business will remain balance sheet cash negative until at least FY22.
